Apart from neuroendocrine tumors, radiopharmaceutical therapy has shown promising results for advanced prostate-specific membrane antigen-positive metastatic prostate cancer, with increasing evidence to support its use as an earlier line of therapy and in earlier disease stages (20–23). The gene discussed is FOLH1; the disease is neuroendocrine neoplasm.